Longevity Analysis: AI vs. Longevity
INTERNAL USE ONLY | Venture Capital Due Diligence Report To: Investment Committee (IC) From: Senior Industry Analyst, Pre-Investment Division Date: January 27, 2026 Subject: Sector Analysis & Strategic Outlook: Longevity & Geroscience (2026) Classification: Confidential 1. Executive Summary & Investment Thesis 1.1 Market Overview The longevity sector has matured from speculative biology into a rigorous clinical engineering discipline. As of Q1 2026: Metric Value Source Longevity Biotech Market Size $31.6B (2026) [1] Projected Market Size (2031) $46.8B [1] Implied CAGR ~8.2% Calculated 1.2 Core Investment Thesis “Clinical Inflection Point” — The 2024–2025 cycle de-risked systemic interventions (TPE, Rapamycin) while filtering out underperforming monotherapies. 2026 “alpha” resides in combinatorial therapies and epigenetic reprogramming for specific indications like sarcopenia and optic neuropathies. ...